Genetic polymorphisms and individualized tacrolimus dosing.

[1]  E. M. Sampaio,et al.  Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. , 2009, Transplantation proceedings.

[2]  B. Charpentier,et al.  Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. , 2008, Basic & clinical pharmacology & toxicology.

[3]  V. Haufroid,et al.  CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  B. Vinet,et al.  Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients , 2006, Pharmacogenetics and genomics.

[5]  J. Squifflet,et al.  Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids , 2005, Transplantation.

[6]  J. Squifflet,et al.  The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. , 2004, Pharmacogenetics.

[7]  P. Beaune,et al.  Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. , 2003, Journal of the American Society of Nephrology : JASN.

[8]  P. Syrris,et al.  Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.

[9]  S. Uemoto,et al.  C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. , 2002, Pharmacogenetics.

[10]  Atholl Johnston,et al.  Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. , 2002, Clinical therapeutics.

[11]  V. Haufroid,et al.  The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function , 2006, Clinical chemistry and laboratory medicine.